Regenerative medicine. The industry comes of age

Abstract

The regenerative medicine industry has moved into a new era in which commercialisation and not research is the number one priority. To achieve its new goal, much has had to change, including the introduction of expert business management, simpler but superior products and scalability of manufacture. Mass public and political support is supplying both long-term resources and the market demand to finally create a sustainable new health-care sector.